Ollie's Bargain Outlet 주식 (NASDAQ: OLLI)

에 대한 최신 뉴스 Ollie's Bargain Outlet (NASDAQ:OLLI) 주식

Ollie's Bargain Outlet

Ollie's Bargain Outlet Holdings Inc is a retailer of brand-name merchandise at drastically reduced prices. It offers customers a selection of brand-name products, including housewares, food, books and stationery, bed and bath, floor coverings, toys, and hardware. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun, and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns. These attributes have driven rapid growth and consistent store performance for the company.

Analyst Color

Legal

OLLI

빅랏츠(NYSE:BIG)의 챕터 11 파산 보호 신청은 경쟁사인 올리스 바겐 아웃렛 홀딩스(NASDAQ:OLLI)에게 성장 기회를 의미할 수 있다고 한 애널리스트가 말했다.

빅랏츠의 파산 신청은 올리스 바겐 아웃렛의 성장 기회를 의미한다고 분석가가 주장

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

RKLB

TALO

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 빌리빌리(NASDAQ:BILI)의 주가는 지난주 &#39;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#39; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 21달러 가격 목표를 발표했다. 

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

Ollie's Bargain Outlet Holdings, Inc. - Common Stock

Ollie's Bargain Outlet Holdings Inc

ARC Global Investments, a major investor in&nbsp;Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), has drastically reduced its stake in the company.
What Happened: According to a regulatory filing on Friday, ARC Global and its manager, Patrick Orlando, now hold a mere 0.01% stake in Trump Media, the parent company of&nbsp;Truth Social.
This is a significant decrease from their previous holding of over 5% or more than&nbsp;11 million shares in September.
Orlando, the former CEO of Digital World Acquisition Corp., the SPAC that took Trump Media public, was <a href="https://www.benzinga.com/news/23/03/31451246/trump-linked-spac-digital-world-boots-out-ceo-as-it-looks-to-bring-in-new-management-to-tackle-unpre">removed from his role</a> before the deal was completed.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/11/41927985/bitcoin-ethereum-consolidate-dogecoin-surges-as-election-rally-takes-a-breather-analyst-says-pullback-typical-for-healthy-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Consolidate, Dogecoin Surges As Election Rally Takes A Breather: Analyst Says Pullback &#8216;Typical&#8217; For Healthy Market</a>
In July, the U.S. Securities and Exchange Commission (SEC) sued Orlando, <a href="https://www.benzinga.com/news/24/07/39829953/trump-linked-digital-worlds-former-ceo-sued-by-sec-for-securities-fraud">alleging securities fraud</a> for false and misleading statements as CEO of Digital World Acquisition.
In September, a Delaware judge ruled that Trump Media had violated an agreement with ARC Global. The ruling stated that the fund should receive over&nbsp;half a million additional shares&nbsp;before the expiration of&nbsp;a lock-up on insider sales.
Why It Matters: President-elect Donald Trump&nbsp;currently holds&nbsp;a <a href="https://www.benzinga.com/markets/equities/24/11/41878254/trumps-djt-surges-26-in-past-month-boosting-investors-wealth-by-over-1b-as-ex-president-returns-to-white-house-for-a-second-term">57% stake in&nbsp;Trump Media</a>.
On Election Day, Trump Media reported a 6% year-over-year decrease in its <a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">third-quarter net sales</a>, which stood at $1.01 million, with all revenue coming from advertising on the Truth Social platform.
Earlier this month, Trump announced that he had no plans to <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">sell his stake in the Truth Social parent</a>, causing the company&#8217;s stock to soar.
Meanwhile, on Wednesday, it was reported that <a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock">Trump Media&#8217;s CFO</a> and two other insiders sold millions of dollars worth of shares following the election.
Price Action: DJT shares ended Friday up 4.11%, closing at $28.10. However, in after-hours trading, the stock dipped 0.57% to $27.94 at the time of writing, according to <a href="https://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41964758/trumps-attorney-general-pick-matt-gaetz-once-proposed-collecting-federal-income-taxes-in-bitcoin-apart-from-co-sponsoring-bill-to-abolish-the-fed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Attorney General Pick Matt Gaetz Once Proposed Collecting Federal Income Taxes In Bitcoin, Apart From Co-sponsoring Bill To Abolish The Fed</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

Tech

Major Investor In Trump Media Offloads Most Of Its Stake In DJT Stock

Elon Musk&#8217;s artificial intelligence venture, xAI, is reportedly in the process of raising up to $6 billion. The funds are intended for purchasing 100,000 Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
What Happened: xAI's latest funding round is expected to close early next week, as reported <a href="https://www.cnbc.com/2024/11/15/elon-musks-xai-raising-up-to-6-billion-to-purchase-100000-nvidia-chips-for-memphis-data-center.html">by</a> CNBC on Friday. It includes $5 billion from Middle Eastern sovereign funds and an additional $1 billion from other investors. Some of these investors may be looking to increase their stakes.
This fundraising would value Musk's AI startup at $50 billion, more than doubling the $24 billion valuation in its <a href="https://www.benzinga.com/news/24/05/39025708/elon-musk-cheers-funding-after-xai-secures-6b-from-sequoia-andreessen-horowitz-saudi-prince-alwaleed">previous round of funding in May</a>.
The chips are crucial for the new Memphis supercomputer, which will support Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Full Self-Driving (FSD) technology.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
xAI, launched in July 2023, aims to &#8220;understand the true nature of the universe,&#8221; according to its website.
Last year, xAI introduced a chatbot named Grok, inspired by &#8220;The Hitchhiker&#8217;s Guide to the Galaxy.&#8221; The chatbot was designed to compete with OpenAI&#8217;s ChatGPT, Google&#8217;s Gemini, and Anthropic&#8217;s Claude.
See Also: <a href="https://www.benzinga.com/24/11/41872302/taylor-swift-fans-abandon-elon-musks-x-for-bluesky-how-trumps-election-victory-triggered-swifties-uprising?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Taylor Swift Fans Abandon Elon Musk&#8217;s X For Bluesky, Says Report</a>
Why It Matters: Earlier this year, <a href="https://www.benzinga.com/news/24/05/39027735/elon-musks-xai-raises-6b-heres-where-it-stands-against-openai-anthropic-and-other-ai-rivals">xAI raised $6 billion</a> in its Series B funding round, catapulting its valuation to $24 billion.
This positioned xAI among the world&#8217;s most valuable AI startups, alongside giants like Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI and Anthropic. Despite this, xAI is not yet the largest AI startup in terms of valuation.
The <a href="https://www.benzinga.com/news/24/06/39199007/elon-musks-xai-to-take-on-tech-giants-microsoft-google-and-openai-with-planned-memphis-supercomputer">planned Memphis supercomputer</a>, a key component of xAI&#8217;s strategy, is set to enhance its AI capabilities. The project, located at a former manufacturing site, is awaiting approval from local authorities. Discussions with city officials began in March, underscoring the competitive nature of securing such high-profile projects.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41964846/openais-operator-ai-agent-will-perform-tasks-like-coding-travel-booking-and-more-launch-expected-in-january-next-year-report">OpenAI&#8217;s &#8216;Operator&#8217; AI Agent Will Perform Tasks Like Coding, Travel Booking And More</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Startups

MSFT

NVDA

TSLA

Elon Musk's xAI Seeks $6B At $50B Valuation To Acquire 100K Nvidia Chips For Memphis Data Center

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

In a report released today, Steven Shemesh from RBC Capital maintained a Buy rating on Ollie's Bargain Outlet Holding (OLLI – Research Report), wit...

RBC Capital Sticks to Its Buy Rating for Ollie's Bargain Outlet Holding (OLLI)

In a report released today, Peter Keith from Piper Sandler maintained a Buy rating on Ollie's Bargain Outlet Holding (OLLI – Research Report), with...

Piper Sandler Remains a Buy on Ollie's Bargain Outlet Holding (OLLI)

Analyst Melanie Nunez of Bank of America Securities reiterated a Buy rating on Ollie's Bargain Outlet Holding (OLLI – Research Report), boosting th...

Buy Recommendation: Ollie's Bargain Outlet Positioned for Growth in Expanding Closeout Market

RBC Capital analyst Steven Shemesh maintained a Buy rating on Ollie's Bargain Outlet Holding (OLLI – Research Report) today and set a price target ...

RBC Capital Reaffirms Their Buy Rating on Ollie's Bargain Outlet Holding (OLLI)

Ollie's Bargain Outlet acquires more former Big Lots stores

In a report released today, Jeremy Hamblin from Craig-Hallum assigned a Buy rating to Ollie's Bargain Outlet Holding (OLLI – Research Report). The ...

Ollie's Bargain Outlet Holding (OLLI) Gets a Buy from Craig-Hallum

Ollie's Bargain Outlet Holding (OLLI) Gets a Buy from RBC Capital

Savers Value Village: A Niche Retail Play That Looks On Sale

Etsy: A Beaten Down Stock With Hidden Value

In a report released today, Peter Keith from Piper Sandler assigned a Buy rating to Ollie's Bargain Outlet Holding (OLLI – Research Report), with a...

Piper Sandler Gives a Buy Rating to Ollie's Bargain Outlet Holding (OLLI)

AMZN

EBAY

ETSY

GLBE

MNSO

Press Releases

OLLIE'S CELEBRATES 31st STATE WITH GRAND OPENING IN WISCONSIN

OLLIE'S RAISES OVER $625,000 FOR CHILDREN'S MIRACLE NETWORK HOSPITALS®

Ollie's Partners with Sunbit to Offer a New Co-Branded Visa Credit Card

Ollie's Bargain Outlet Holdings, Inc. Announces Second Quarter Fiscal 2024 Release Date and Conference Call Information

OLLIE'S CELEBRATES GRAND OPENING OF PRINCETON, IL DISTRIBUTION CENTER

OLLIE'S CELEBRATES GRAND OPENING AND RIBBON CUTTING AT NEW ILLINOIS DISTRIBUTION CENTER

Ollie's Bargain Outlet Holdings, Inc. Reports Second Quarter Fiscal 2024 Financial Results

OLLIE'S CELEBRATES 10 GRAND OPENINGS IN TEXAS

Ollie's Bargain Outlet Acquires Former Big Lots Stores

Ollie's Bargain Outlet Acquires Additional Former Big Lots Stores

Amazon.com

Alibaba Group Holding Limited American Depositary Shares each representing eight Ordinary share

Alibaba Gr Hldgs

Baozun

Coupang

Dillard's

1stdibs.com

eBay

Etsy

Global E Online

Groupon

D-Market Electronic Services & Trading - American Depositary Shares

D-MARKET Electronic

JD.com, Inc. - American Depositary Shares

JD.com

Jumia Technologies AG American Depositary Shares, each representing two Ordinary Shares

Jumia Technologies

Nordstrom

Kohl's

LightInTheBox Holding Co., Ltd. American Depositary Shares, each representing twelve ordinary shares

LightInTheBox Holding

ContextLogic

Macy's

MercadoLibre

MINISO Group Holding Limited American Depositary Shares, each representing four Ordinary Shares

MINISO Group Holding

PDD Holdings Inc. - American Depositary Shares

PDD Holdings

Qurate Retail, Inc. - Series A Common Stock

Qurate Retail

Qurate Retail, Inc. - Series B Common Stock

Savers Value Village

Vipshop Holdings Limited American Depositary Shares, each representing two ordinary shares

Vipshop Holdings

Piper Sandler

RBC Capital

B of A Securities

Loop Capital

JP Morgan

빅랏츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>)의 <a href="https://www.benzinga.com/markets/equities/24/09/40767067/another-retailer-takes-chapter-11-route-big-lots-files-for-bankruptcy-and-agrees-to-sell-assets-">챕터 11 파산 보호 신청</a>은 경쟁사인 올리스 바겐 아웃렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)에게 성장 기회를 의미할 수 있다고 한 애널리스트가 말했다.
오하이오주 콜럼버스에 본사를 둔 이 할인 소매업체는 월요일 모든 자산과 지속적인 사업 운영을 투자 회사인 넥서스 캐피털 매니지먼트(Nexus Capital Management)의 계열사에 매각할 것이라고 확인했다. 이는 일부 소매점을 폐쇄하는 결정도 포함된다고 밝혔다.
올리스는 매장 수를 현재 525개 매장에서 장기 포화 목표인 1,300개 매장으로 늘리기 위해 노력하고 있기 때문에 폐쇄된 빅랏츠 위치를 인수할 기회가 있을 수 있다고 J.P.모건 체이스의 분석가인 매튜 보스(Matthew Boss)가 말했다.
올리스는 또한 매장 중 430개가 빅랏츠 매장과 가까운 거리에 있다는 사실로부터 이익을 얻을 수 있다고 그가 말했다.
그는 월요일 메모에서 &#8220;우리는 측면 폐점 소매업체인 OLLI를 트래픽 증가의 주요 수혜자로 보고 있으며 빅랏츠 매장에서 5마일 이내에 있는 OLLI의 525개 매장 중 80-85%를 차지하는 지갑 점유율을 가속화하고 있다&#8221;고 썼다.
8월 29일 현재 소매점 1,392개 중 296개를 폐쇄하려는 빅랏츠의 계획은 올리스가 현재 말까지 매장 수를 560개로 늘린 후 2025 회계연도와 2026 회계연도 동안 매장 수를 13.5% 늘리는 데 도움이 될 수 있다고 보스가 말했다. 매장과 시장 점유율의 이러한 성장은 올리스의 총 이익률을 40.5%에서 41%로 높이는 데 도움이 될 수 있다.
주가 움직임: 월요일 빅랏츠의 주가는 애프터 마켓 거래에서 40.22% 하락하여 30센트로 떨어졌다. 올리스는 월요일 정규 거래에서 5.92% 상승하여 92.48달러로 마감했다.
사진: Robert V. Schwemmer via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

Ollie's Bargain Outlet

뉴스

에 대한 최신 뉴스 Ollie's Bargain Outlet (NASDAQ:OLLI) 주식

월요일, 9월 09, 2024

월요일, 6월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌